logo
TenderSpecial Notice

Notice Of Intent: Lutathera® (Lutetium Lu 177 Dotatate) And Pluvicto™ (Lutetium Lu 177 Vipivotide Tetraxetan)

Special notice · Maryland

Source: SAM.gov

The Defense Health Agency (DHA), Healthcare Contracting Division – Northeast (HCD-NE), Department of Radiology at Walter Reed National Military Medical Center (WRNMMC), intends to award a firm fixed price contract on a sole source basis to Novartis Pharmaceuticals Corporation (Cage: 04520). The anticipated award will be made under the statutory authority permitting Other than Full and Open Competi

Status
Prospective
Sector
Aerospace & Defense, Government, Commercial, Residential, Manufacturing (Industrial), Hospital
Location
Bethesda, Maryland, United States of America
Updated
3 Nov 2026
Source
SAM.gov

ConstructChat

Ask ConstructChat about Notice Of Intent: Lutathera® (Lutetium Lu 177 Dotatate) And Pluvicto™ (Lutetium Lu 177 Vipivotide Tetraxetan)

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Tender Information FAQ

Tender Information

3 Q
The tender “Notice Of Intent: Lutathera® (Lutetium Lu 177 Dotatate) And Pluvicto™ (Lutetium Lu 177 Vipivotide Tetraxetan)” is a tender record in Taiyo, linked to the Aerospace & Defense sector. It is issued for works, goods, or services related to Bethesda, Maryland, United States of America.

Participants

Not available for this record.

Status

Original status

special notice

Taiyo status

Prospective

Taiyo last update

2026-11-03

Contact

Not available for this record.

Description

Description

The Defense Health Agency (DHA), Healthcare Contracting Division – Northeast (HCD-NE), Department of Radiology at Walter Reed National Military Medical Center (WRNMMC), intends to award a firm fixed price contract on a sole source basis to Novartis Pharmaceuticals Corporation (Cage: 04520). The anticipated award will be made under the statutory authority permitting Other than Full and Open Competition pursuant to FAR 6.302-1 “Only one responsible source and no other supplies or services will satisfy agency requirements”. The contract is intended to procure LUTATHERA® (lutetium Lu 177 dotatate) and PLUVICTO™ (lutetium Lu 177 vipivotide tetraxetan) exclusively developed, manufactured, and supplied by Novartis Pharmaceuticals Corporation (Cage: 04520). This notice of intent is NOT a request for competitive proposals or quotations. Requests for copies of a solicitation in response to this notice will not be honored or acknowledged. Phone calls will not be accepted. A determination by the Government to not compete this proposed action based upon response to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether conducting a competitive procurement is in the best interest of the Government. Interested parties may identify their interest and capabilities by responding to this notice no later than 5pm on June 4, 2026 by email to claudia.a.febresmormontoy.ctr@health.mil. All information submitted should support the offeror’s capability to provide the training required and shall be furnished at no cost or obligation to the Government.

Original sector

Not Identified

Location

Country

United States of America (USA)

State

Maryland

City

Bethesda

Source

Source

SAM.gov

URL

More Details

Record type

Tender

Sector

Aerospace & Defense, Government, Commercial, Residential, Manufacturing (Industrial), Hospital

Article published date

2026-05-15

More on this tender

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this tender
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this tender